---
title: Full-Body Computed Tomography Screening
author: Steve Simon
date: 2004-09-06
categories:
- Blog post
tags:
- Diagnostic testing
output: html_document
page_update: partial
---
Full body scans represent a good example of the conflicting
considerations when you need to evaluate a screening test. A full body
scan uses a CT (Computerized Tomography) scan to examine the inside of
your body. These full body scans are heavily advertised as a way to
detect physiologic abnormalities that might provide an early warning of
cancer, heart disease, or other illnesses.

Many organizations, including the U.S. Food and Drug Administration
strongly discourage the use of full body scans in healthy adults with no
obvious symptoms of disease.

Other procedures, such as the use of Prostate Specific Antigen to
diagnose prostate cancer, and mammograms to detect breast cancer, are
also subject to a lively debate about the risks and benefits of using
them for routine screening. The issues here are more complex, and there
are both defenders and opponents of the use of these tests for screening
in healthy adults.

To evaluate a screening procedure, you need to evaluate the risks of the
procedure, and assess the costs of a false positive and the costs of a
false negative. You then need to see how frequently the disease occurs
in this population, and you might modify this estimate to take into
account special features of the types of patients that you yourself see.
Finally, is there anything about this particular patient that would
cause you to modify the estimates of prevalence further. And do the
values of this particular patient warrant a re-evaluation of the costs
and benefits of the screening?

A recent publication in Radiology mentions the rather large dose of
radiation that a full-body scan produces and estimates an increase in
the lifetime risk of risk of cancer mortality of 0.08%. This translates
into an NNH of 1,250. For every 1,250 people who receive a single full
body scan, you will see one additional death from cancer

This gives a solid reference point for evaluating the possible benefits
of whole body scans. If they detect diseases in only one out of every
thousand people, then the harms of screening might outweigh the
benefits.

The costs of a false positive really represent the costs of additional
testing. Beyond just the money, some of the additional tests carry
significant risks of side effects. One of the additional tests for
prostate cancer for example, a prostate biopsy, carries the risk of
bleeding and infection.

The costs of a false negative represents the costs of leaving a disease
undiagnosed until it manifests itself in a more overt manner. Sometimes
the costs of a false negative is less than you might think. For
mammography, as an example, leaving a tumor undetected may not be a bad
thing. If the tumor develops slowly, then it will eventually be detected
by other means before it has had a chance to spread. If a tumor develops
rapidly, then by the time it is detected by mammography, it may be too
late. It is, perhaps, only the "Goldilocks" tumors, those that grow
not too fast and not too slow, that are worth detecting early.

The prevalence of disease is also very important. In a population of
people with no overt signs of disease and no obvious risk factors,
whole-body scans may be looking for a needle in a haystack. The few
diseases discovered are more than counterbalanced by the costs and risks
associated with the screening. In a different population, though, such
screening may make more sense. The FDA, for example, mentions on-going
research in the use of whole body scans for people at high risk of lung
or colon cancer. Regular mammograms are much easier to justify for women
who have had a relative who has died from breast cancer.

I discuss some of the controversies associated with the PSA test in my
May 31, 2004 weblog entry. When I get the chance, I will discuss some of
the controversies associated with mammography.

**Estimated Radiation Risks Potentially Associated with Full-Body CT
Screening.** Brenner DJ, Elliston CD. Radiology 2004: 232(3); 735-8.
[\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15273333&dopt=Abstract)
[\[Abstract\]](http://radiology.rsnajnls.org/cgi/content/abstract/232/3/735)
[\[Full
text\]](http://radiology.rsnajnls.org/cgi/content/full/232/3/735)
[\[PDF\]](http://radiology.rsnajnls.org/cgi/reprint/232/3/735.pdf)

**Women aged over 40 who are at increased risk of breast cancer should
get annual mammograms.** Kmietowicz Z. Bmj 2004: 328(7455); 1515.
[\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15217851&dopt=Abstract)
[\[Full
text\]](http://bmj.bmjjournals.com/cgi/content/full/328/7455/1515)
[\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/328/7455/1515.pdf)

**[The Prostate-Specific Antigen (PSA) Test: Questions and
Answers](http://cis.nci.nih.gov/fact/5_29.htm)**. U.S. Department of
Health & Human Services, National Cancer Institute. Accessed on
2004-09-06. cis.nci.nih.gov/fact/5\_29.htm

**[Full-Body CT Scans. What You Need to
Know](http://www.fda.gov/cdrh/ct/ctscansbro.html)**. U.S. Food and Drug
Administration. Accessed on 2004-09-06.
www.fda.gov/cdrh/ct/ctscansbro.html

**Other references**

-   **Antenatal screening and its possible meaning from unborn baby's
    perspective.** Aksoy S. BMC Med Ethics 2001: 2(1); 3.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11389776&dopt=Abstract)
    [\[Abstract\]](http://www.biomedcentral.com/1472-6939/2/3/abstract)
    [\[Full text\]](http://www.biomedcentral.com/1472-6939/2/3)
    [\[PDF\]](http://www.biomedcentral.com/content/pdf/1472-6939-2-3.pdf)
-   **Occult pneumonias: empiric chest radiographs in febrile children
    with leukocytosis.** Bachur R, Perry H, Harper MB. Annals of
    Emergency Medicine 1999: 33(2); 166-73.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9922412&dopt=Abstract)
-   **The mammography controversy.** Begg CB. Oncologist 2002: 7(3);
    174-6.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12065786&dopt=Abstract)
    [\[Full
    text\]](http://theoncologist.alphamedpress.org/cgi/content/full/7/3/174)
    [\[PDF\]](http://theoncologist.alphamedpress.org/cgi/reprint/7/3/174.pdf)
-   **Estimated Radiation Risks Potentially Associated with Full-Body CT
    Screening.** Brenner DJ, Elliston CD. Radiology 2004: 232(3); 735-8.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15273333&dopt=Abstract)
    [\[Abstract\]](http://radiology.rsnajnls.org/cgi/content/abstract/232/3/735)
    [\[Full
    text\]](http://radiology.rsnajnls.org/cgi/content/full/232/3/735)
    [\[PDF\]](http://radiology.rsnajnls.org/cgi/reprint/232/3/735.pdf)
-   **Effect of false-positive mammograms on interval breast cancer
    screening in a health maintenance organization.** Burman ML, Taplin
    SH, Herta DF, Elmore JG. Annals of Internal Medicine 1999: 131(1);
    1-6.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10391809&dopt=Abstract)
-   **Percentage of free prostate-specific antigen in sera predicts
    aggressiveness of prostate cancer a decade before diagnosis.**
    Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P, Chan DW,
    Fozard JL, Pearson JD. Urology 1997: 49(3); 379-84.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9123702&dopt=Abstract)
-   **[Screening](http://bmj.com/epidem/epid.a.html)**. Coggon D, Rose
    G, Barker D, BMJ. Accessed on 2003-09-08. bmj.com/epidem/epid.a.html
-   **Ten-year risk of false positive screening mammograms and clinical
    breast examinations.** Elmore JG, Barton MB, Moceri VM, Polk S,
    Arena PJ, Fletcher SW. N Engl J Med 1998: 338(16); 1089-96.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9545356&dopt=Abstract)
    [\[Abstract\]](http://content.nejm.org/cgi/content/abstract/338/16/1089)
    [\[Full
    text\]](http://content.nejm.org/cgi/content/full/338/16/1089)
    [\[PDF\]](http://content.nejm.org/cgi/reprint/338/16/1089.pdf)
-   **Neonatal examination and screening trial (NEST): a randomised,
    controlled, switchback trial of alternative policies for low risk
    infants.** Glazener CM, Ramsay CR, Campbell MK, Booth P, Duffty P,
    Lloyd DJ, McDonald A, Reid JA. British Medical Journal 1999:
    318(7184); 627-31.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10066201&dopt=Abstract)
    [\[Abstract\]](http://bmj.bmjjournals.com/cgi/content/abstract/318/7184/627)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/318/7184/627)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/318/7184/627.pdf)
-   **Is screening for breast cancer with mammography justifiable?**
    Gotzsche P, Olsen O. Public Health 2000: 355(9198); 129-134.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10675181&dopt=Abstract)
-   **Is screening for breast cancer with mammography justifiable?
    \[Commentary: a compilation of comments RE:Assessment of nationwide
    cancer-screening programmes\].** Gotzsche P, Olsen O. The Lancet
    2000: 355(9198); 129-34.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10675181&dopt=Abstract)
-   **Uses and abuses of screening tests.** Grimes DA, Schulz KF. Lancet
    2002: 359; 881-884.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11897304&dopt=Abstract)
    [\[Abstract\]](http://dx.doi.org/10.1016/S0140-6736(02)07948-5)
-   **A randomised study of screening for colorectal cancer using faecal
    occult blood testing: results after 13 years and seven biennial
    screening rounds.** Jorgensen OD, Kronborg O, Fenger C. Gut 2002:
    50(1); 29-32.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11772963&dopt=Abstract)
    [\[Abstract\]](http://gut.bmjjournals.com/cgi/content/abstract/50/1/29)
-   **Women aged over 40 who are at increased risk of breast cancer
    should get annual mammograms.** Kmietowicz Z. Bmj 2004: 328(7455);
    1515.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15217851&dopt=Abstract)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/328/7455/1515)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/328/7455/1515.pdf)
-   **Bush plans to screen whole US population for mental illness.**
    Lenzer J. Bmj 2004: 328(7454); 1458.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15205287&dopt=Abstract)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/328/7454/1458)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/328/7454/1458)
-   **C-reactive protein\--to screen or not to screen?** Mosca L. N Engl
    J Med 2002: 347(20); 1615-7.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12432050&dopt=Abstract)
-   **Protective effect of faecal occult blood test screening for
    colorectal cancer: worse prognosis for screening refusers.** Niv Y,
    Lev-El M, Fraser G, Abuksis G, Tamir A. Gut 2002: 50(1); 33-37.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11772964&dopt=Abstract)
    [\[Abstract\]](http://gut.bmjjournals.com/cgi/content/abstract/50/1/33)
-   **Screening for breast cancer with mammography.** Olsen O, Gotzsche
    PC. Cochrane Database Syst Rev 2001: (4); CD001877.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11687128&dopt=Abstract)
-   **Screening for gestational diabetes mellitus. A simple test may
    make it easier to study whether screening is worthwhile \[editorial;
    comment\].** Rey E. British Medical Journal 1999: 319(7213);
    798-799.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10496805&dopt=Abstract)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/319/7213/798)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/319/7213/798.pdf)
-   **Comparison of C-reactive protein and low-density lipoprotein
    cholesterol levels in the prediction of first cardiovascular
    events.** Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. N Engl J
    Med 2002: 347(20); 1557-65.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12432042&dopt=Abstract)
-   **What Is the Yield of Screening Echocardiography in Pediatric
    Syncope?** Ritter S, Tani LY, Etheridge SP, Williams RV, Craig JE,
    Minich LL. Pediatrics 2000: 105(5); E58.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10799622&dopt=Abstract)
-   **The risks of screening: data from the Nottingham randomised
    controlled trial of faecal occult blood screening for colorectal
    cancer.** Robinson MHE, Hardcastle J, Moss S, Amar S, Chamberlain J,
    Armitage N, Scholefield J, Mangham C. Gut 1999: 45(4); 588-592.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10486370&dopt=Abstract)
-   **Screening in clinical trials.** Sass J, Pascoe-Gonzalez S,
    Lehnert W. Lancet 2002: 360(9337); 952.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12354503&dopt=Abstract)
-   **Neuroblastoma Screening at One Year of Age.** Schilling FH, Spix
    C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J,
    Schwarz K, Treuner J, Zorn U, Michaelis J. N Engl J Med 2002:
    346(14); 1047-1053.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11932471&dopt=Abstract)
    [\[Abstract\]](http://content.nejm.org/cgi/content/abstract/346/14/1047)
    [\[Full
    text\]](http://content.nejm.org/cgi/content/full/346/14/1047)
    [\[PDF\]](http://content.nejm.org/cgi/reprint/346/14/1047.pdf)
-   **Effect of faecal occult blood screening on mortality from
    colorectal cancer: results from a randomised controlled trial.**
    Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Gut 2002:
    50(6); 840-844.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12010887&dopt=Abstract)
    [\[Abstract\]](http://gut.bmjjournals.com/cgi/content/abstract/50/6/840)
-   **Prospective cohort study of routine use of risk assessment scales
    for prediction of pressure ulcers.** Schoonhoven L, Haalboom JR,
    Bousema MT, Algra A, Grobbee DE, Grypdonck MH, Buskens E. Bmj 2002:
    325(7368); 797.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12376437&dopt=Abstract)
-   **Prolongation of the QT interval and the sudden infant death
    syndrome.** Schwartz PJ, Stramba-Badiale M, Segantini A, Austoni P,
    Bosi G, Giorgetti R, Grancini F, Marni ED, Perticone F, Rosti D,
    Salice P. N Engl J Med 1998: 338(24); 1709-14.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9624190&dopt=Abstract)
    [\[Abstract\]](http://content.nejm.org/cgi/content/abstract/338/24/1709)
    [\[Full
    text\]](http://content.nejm.org/cgi/content/full/338/24/1709)
    [\[PDF\]](http://content.nejm.org/cgi/reprint/338/24/1709.pdf)
-   **Women need better information about routine mammography.**
    Thornton H, Edwards A, Baum M. Bmj 2003: 327(7406); 101-3.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12855532&dopt=Abstract)
    [\[Full text\]](http://bmj.com/cgi/content/full/327/7406/101)
    [\[PDF\]](http://bmj.com/cgi/reprint/327/7406/101.pdf)
-   **A systematic review of the effects of screening for colorectal
    cancer using the faecal occult blood test, hemoccult.** Towler B,
    Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. Bmj 1998:
    317(7158); 559-65.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9721111&dopt=Abstract)
    [\[Abstract\]](http://bmj.bmjjournals.com/cgi/content/abstract/317/7158/559)
    [\[Full
    text\]](http://bmj.bmjjournals.com/cgi/content/full/317/7158/559)
    [\[PDF\]](http://bmj.bmjjournals.com/cgi/reprint/317/7158/559.pdf)
-   **[The Prostate-Specific Antigen (PSA) Test: Questions and
    Answers](http://cis.nci.nih.gov/fact/5_29.htm)**. U.S. Department of
    Health & Human Services, National Cancer Institute. Accessed on
    2004-09-06. cis.nci.nih.gov/fact/5\_29.htm
-   **[Full-Body CT Scans. What You Need to
    Know](http://www.fda.gov/cdrh/ct/ctscansbro.html)**. U.S. Food and
    Drug Administration. Accessed on 2004-09-06.
    www.fda.gov/cdrh/ct/ctscansbro.html
-   **When can a risk factor be used as a worthwhile screening test?**
    Wald NJ, Hackshaw A, Frost C. British Medical Journal 1999:
    319(7224); 1562-1565.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10591726&dopt=Abstract)
    [\[Full text\]](http://bmj.com/cgi/content/full/319/7224/1562)
    [\[PDF\]](http://bmj.com/cgi/reprint/319/7224/1562.pdf)
-   **Surgery and the reduction of mortality from prostate cancer.**
    Walsh PC. N Engl J Med 2002: 347(11); 839-40.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12226156&dopt=Abstract)
    [\[Abstract\]](http://content.nejm.org/cgi/content/extract/347/11/839)
-   **Case-control studies of the efficacy of screening tests designed
    to prevent the incidence of cancer.** Weiss NS. Am J Epidemiol 1999:
    149(1); 1-4.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9883787&dopt=Abstract)
-   **Can the initial clinical assessment of thyroid function be
    improved?** White GH, Walmsley RN. Lancet 1978: 2(8096); 933-5.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=81941&dopt=Abstract)
-   **Future of preschool vision screening: Conclusions for or against
    services are invalid without appropriate research evidence \[a
    compilation of letters RE: Future of preschool vision screening\].**
    Williams C, Harrad R, Sparrow J, Harvey I, Golding J. BMJ 1998:
    316(7135); 937-940.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9569402&dopt=Abstract)
-   **Colorectal cancer screening: Now is the time.** Winawer SJ, Zauber
    AG. Canadian Medical Association Journal 2000: 163(5); 543-544.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11006765&dopt=Abstract)
    [\[Full text\]](http://www.cmaj.ca/cgi/content/full/163/5/543)
    [\[PDF\]](http://www.cmaj.ca/cgi/reprint/163/5/543.pdf)
-   **The validity of urine examination for urinary tract infections in
    daily practice.** Winkens RA, Leffers P, Trienekens TA, Stobberingh
    EE. Fam Pract 1995: 12(3); 290-3.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8536832&dopt=Abstract)
-   **Screening of Infants and Mortality Due to Neuroblastoma.** Woods
    WG, Gao R-N, Shuster JJ, Robison LL, Bernstein M, Weitzman S, Bunin
    G, Levy I, Brossard J, Dougherty G, Tuchman M, Lemieux B. N Engl J
    Med 2002: 346(14); 1041-1046.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11932470&dopt=Abstract)
    [\[Abstract\]](http://content.nejm.org/cgi/content/abstract/346/14/1041)
    [\[Full
    text\]](http://content.nejm.org/cgi/content/full/346/14/1041)
    [\[PDF\]](http://content.nejm.org/cgi/reprint/346/14/1041.pdf)
-   **Screening for prostate cancer: the roles of science, policy, and
    opinion in determining what is best for patients.** Woolf SH,
    Rothemich SF. Annu Rev Med 1999: 50; 207-21.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10073273&dopt=Abstract)
-   **Review: 4 clinical tests most accurately predict poor outcome in
    patients with anoxic-ischemic coma.** Zandbergen E. ACP Journal Club
    1999: 131(1); 22.
-   **Mass screening for rectal neoplasm in Jiashan County, China.**
    Zheng GM, Choi BC, Yu XR, Zou RB, Shao YW, Ma XY. J Clin Epidemiol
    1991: 44(12); 1379-85.
    [\[Medline\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1753269&dopt=Abstract)
-   **Comparing accuracies of two screening tests in a two-phase study
    for dementia.** Zhou X-H. Appl. Statist. 1998: 47(1); 135-47.

You can find an [earlier version](http://www.pmean.com/04/FullBodyScan.html) of this page on my [original website](http://www.pmean.com/original_site.html).
